Summit Therapeutics Inc. has made headlines with the recent exercise of stock options by Co-Chief Executive Officer Mahkam Zanganeh. On November 20, 2026, Zanganeh exercised an option to purchase 300,000 shares of the company’s common stock at a price of $1.06 per share. This transaction signifies a strong belief in the company's potential and future growth, particularly within the pharmaceutical preparations industry.

Background

Summit Therapeutics Inc. operates in the pharmaceutical preparations sector, as indicated by its Standard Industrial Classification (SIC) code of 2834. The company trades under the ticker symbol SMMT on the Nasdaq exchange. It is categorized as a large accelerated filer and has a fiscal year ending on December 31. Recent filings include a mix of Form 4 and Form 8-K submissions, indicating ongoing corporate activity.

What the Filing Says

The SEC filing reveals that Zanganeh acquired the shares through an option exercise, stating, "On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share." Following this transaction, Zanganeh holds a total of 831,000 shares directly.

Impact

This stock option exercise may affect various stakeholders, including shareholders and employees, as it reflects confidence from the leadership. Zanganeh's actions could influence investor sentiment and potentially impact the company's stock performance. The filing also indicates that Zanganeh is not only a director and officer but also a ten-percent owner of the company, which underscores the significance of this transaction.

What's Next

The filing does not say what happens next.